Insilico Medicine and MobiDrop signed an agreement integrating AI-ready single-cell multiomics data into the Pharma.AI platform.

Insilico Medicine and MobiDrop signed a strategic cooperation agreement on September 7. Their collaboration covers the production, integration and use of high-quality, traceable and AI-ready single-cell data.

Multiomics data produced at scale by MobiDrop will be systematically added to the data warehouse of Insilico Medicine’s Pharma.AI platform. The source describes a data-infrastructure integration rather than an equity investment, acquisition or completed drug-development milestone.

The data will support training, validation and model iteration for PandaOmics, Insilico Medicine’s generative-biology platform. It will also be used for the company’s recently released multi-agent-driven Virtual Aging Cell platform, abbreviated VAC.

The source does not disclose the agreement’s financial value, data volume, exclusivity, duration or ownership terms. It also provides no performance results showing the effect of the added data on model accuracy or drug-development outcomes.